Kooperativer Bibliotheksverbund

UID:

Format: 1 Online-Ressource (viii, 288 Seiten) : , Illustrationen.

ISBN: 978-981-1607-80-6

Additional Edition: Erscheint auch als Druck-Ausgabe, Hardcover ISBN 978-981-1607-79-0

Additional Edition: Erscheint auch als Druck-Ausgabe, Paperback ISBN 978-981-1607-82-0

Language: English

DOI: 10.1007/978-981-16-0780-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (XI, 177 Seiten) : , Illustrationen.

ISBN: 978-981-1965-21-0

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1965-20-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1965-22-7

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1965-23-4

Language: English

DOI: 10.1007/978-981-19-6521-0

URL: Volltext  (URL des Erstveröffentlichers)

URL: Volltext  (URL des Erstveröffentlichers)

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (viii, 288 Seiten) : , Illustrationen.

ISBN: 978-981-1607-80-6

Additional Edition: Erscheint auch als Druck-Ausgabe, Hardcover ISBN 978-981-1607-79-0

Additional Edition: Erscheint auch als Druck-Ausgabe, Paperback ISBN 978-981-1607-82-0

Language: English

DOI: 10.1007/978-981-16-0780-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (viii, 288 Seiten) : , Illustrationen.

ISBN: 978-981-1607-80-6

Additional Edition: Erscheint auch als Druck-Ausgabe, Hardcover ISBN 978-981-1607-79-0

Additional Edition: Erscheint auch als Druck-Ausgabe, Paperback ISBN 978-981-1607-82-0

Language: English

DOI: 10.1007/978-981-16-0780-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (VIII, 609 p. 1 illus).

Edition: 1st ed. 2022

ISBN: 978-981-1905-19-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1905-18-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1905-20-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1905-21-6

Language: English

Subjects: Biology

DOI: 10.1007/978-981-19-0519-3

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: VIII, 391 p. 3 illus. in color. , online resource.

Edition: 1st ed. 2024.

ISBN: 9789819746279

Content: This book provides a comprehensive overview of plants and plant-derived phytochemicals in the management of cardiovascular diseases. It presents the cardioprotective potential of plants and phytochemicals, covering various preclinical models, assays, and clinical research protocols of plant medicine for cardioprotection. Chapters cover the role of plants and phytochemicals in prevention and cure of atherosclerosis, hypertension, cardiomyopathy, arrhythmia, myocardial ischemia, cardiotoxicity and the underlying pharmacological, molecular, biochemical, and immunobiological mechanisms. The book also includes toxicological aspects (safety evaluations), meta-analysis of clinical trials, critical assessments, drawbacks and challenges for adopting phytomedical approaches in evidence-based medicine for the treatment of CVDs. Screening methods and plant foods for cardioprotection are also covered. The book will be a reference for all researchers working on the role of plant-based products on cardiovascular systems and on cardioprotective agents of plant origin. It will be useful for students, researchers, physicians, nurses, industrial scientists, nutritionists, pharmacists, pharmacologists, toxicologists, botanists, and traditional medicine practitioners. In particular, researchers working on heart problems, diseases, toxicity, physicians treating patients with heart problems, hospitals, pharmacy institutions, pharmacy students and researchers, ethnobotanists, and people working in traditional medicine will find this book useful.

Note: Chapter 1. Cardiovascular system, its functions, and disorders -- Chapter 2. Screening methods and models for evaluation of cardioprotective plants and phytochemicals -- Chapter 3. Plants and phytochemicals for atherosclerosis (including control of blood lipids) -- Chapter 4. Plants and phytochemicals for hypertension -- Chapter 5. Plants and phytochemicals for cardiomyopathy -- Chapter 6. Plants and phytochemicals for arrhythmia -- Chapter 7. Plants and phytochemicals for myocardial ischemia -- Chapter 8. Plants and phytochemicals for myocardial ischemia-reperfusion injury -- Chapter 9. Plants and phytochemicals for aortic aneurysm -- Chapter 10. Plants and phytochemicals for diabetic heart disease -- Chapter 11. Plants and phytochemicals for chemotherapy-induced cardiotoxicity -- Chapter 12. Plants and phytochemicals for pharmaceutical agents-induced cardiotoxicity -- Chapter 13. Plants and Phytochemicals for Heart stroke -- Chapter 14. Plants and phytochemical for antiobesity -- Chapter 15. Plant food with cardioprotective properties -- Chapter 16. Polyherbal formulations for Cardioprotection -- Chapter 17. Ethnomedicinal plants for Cardioprotection -- Chapter 18. Challenges in herbal drug development for cardioprotection -- Chapter 19. Regulatory toxicology aspects of cardioprotective plants and phytochemicals.

In: Springer Nature eBook

Additional Edition: Printed edition: ISBN 9789819746262

Additional Edition: Printed edition: ISBN 9789819746286

Additional Edition: Printed edition: ISBN 9789819746293

Language: English

DOI: 10.1007/978-981-97-4627-9

URL: https://doi.org/10.1007/978-981-97-4627-9

URL: Volltext  (URL des Erstveröffentlichers)

URL: lizenzpflichtig

URL: Cover

UID:

Format: 1 Online-Ressource (viii, 210 Seiten) : , Illustrationen, Diagramme, Karten.

ISBN: 978-981-137-627-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-137-626-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-137-628-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-137-629-0

Language: English

DOI: 10.1007/978-981-13-7627-6

URL: Volltext  (URL des Erstveröffentlichers)

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (VIII, 609 p. 1 illus).

Edition: 1st ed. 2022

ISBN: 978-981-1905-19-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1905-18-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1905-20-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1905-21-6

Language: English

Subjects: Biology

DOI: 10.1007/978-981-19-0519-3

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 online resource (356 pages)

ISBN: 0-323-90952-3 , 0-323-90951-5

Note: Intro -- Paclitaxel: Sources, Chemistry, Anticancer Actions, and Current Biotechnology -- Copyright -- Contents -- Contributors -- Preface -- 1 Introduction to cancer and treatment approaches -- 1.1 Introduction -- 1.2 About cancer biology: Causes and risk factors -- 1.3 Cancer types, classification, and grading -- 1.4 Therapeutic interventions for cancer -- 1.4.1 Surgical excision: A traditional and the effective one -- 1.4.1.1 Robotic-assisted surgery -- 1.4.2 Radiotherapy -- 1.4.2.1 Side effects of radiotherapy -- 1.4.3 Immunotherapy -- 1.4.3.1 Immune checkpoint inhibitors -- 1.4.3.2 Immunotherapy boosted by metronomic chemotherapy -- 1.4.4 Chemotherapy -- 1.4.4.1 History of chemotherapy -- 1.4.4.2 The principal mechanisms of chemotherapy -- 1.4.4.3 Classes of chemotherapeutic agents and their uses -- Alkylating agents -- Antimetabolites -- Anthracyclines (Anti-tumor antibiotics) -- Plant-derived anticancerous agents -- Vinca Alkaloids (VA) -- Taxanes -- Camptothecin (CPT) and its derivatives -- 1.5 Advanced approaches for cancer treatment -- 1.5.1 Nanomedicines -- 1.5.2 Extracellular vesicles as drug delivery systems and diagnostic tool -- 1.5.3 Genome-based methods for cancer treatment -- 1.5.4 Thermal ablation and magnetic hyperthermia -- 1.6 Conclusions -- References -- 2 Taxol: Occurrence, chemistry, and understanding its molecular mechanisms -- 2.1 Introduction -- 2.2 About taxol and its discovery -- 2.3 Natural resources of taxol -- 2.4 Chemistry of taxol -- 2.5 Mechanisms of action of taxol -- 2.6 Conclusion and future prospects -- References -- 3 Taxol: Mechanisms of action against cancer, an update with current research -- 3.1 The discovery and evolution of Paclitaxel (Taxol) -- 3.2 Paclitaxel (Taxol) induces mitotic cell cycle arrest -- 3.2.1 Taxol induces microtubules stabilization. , 3.2.2 Mitotic slippage -- 3.2.3 Paclitaxel's effect is dose-dependent -- 3.3 Taxol induces gene-directed apoptosis -- 3.3.1 Roles of Bcl-2 family in Taxol-induced apoptosis -- 3.3.2 Taxol activates JNK/SAPK to promote cell apoptosis -- 3.4 Taxol and calcium-dependent apoptosis -- 3.4.1 ER-calcium dependent apoptosis -- 3.4.2 Crosstalk between Bcl-2 and calcium homeostasis -- 3.5 Immunomodulation effects by Taxol -- 3.5.1 Taxol and regulatory T cells (Tregs) -- 3.5.2 Taxol and macrophages -- 3.5.3 Taxol and TLR4-dependent pathway -- 3.5.4 Taxol affects macrophages polarization -- 3.6 Resistance mechanisms of Taxol -- 3.6.1 Increased drug efflux by multi-drug resistance (MDR-1) -- 3.6.2 Altered expression of β -tubulins isotypes -- 3.6.3 Upregulation of Bcl-2 family proteins -- 3.7 Conclusion -- Acknowledgment -- References -- 4 Application of nanocarriers for paclitaxel delivery and chemotherapy of cancer -- 4.1 Introduction -- 4.2 Nanoparticles -- 4.2.1 Pharmaceutical aspects of polymeric NPs preparation -- 4.2.2 Recent preclinical studies on paclitaxel NPs -- 4.3 Liposomes -- 4.3.1 Pharmaceutical aspects of liposome preparation -- 4.3.2 Recent preclinical studies on liposomes -- 4.4 Dendrimers -- 4.5 Micelles -- 4.6 Nanotubes -- 4.7 Niosomes -- 4.8 Proniosomes -- 4.9 Ethosomes -- 4.10 Microparticles -- 4.11 Carbon dots -- 4.12 Clinical trials -- 4.13 Overcoming paclitaxel resistance by using Nanocarriers -- 4.14 Selected patents for paclitaxel formulations -- 4.15 Conclusion -- References -- 5 Strategies for enhancing paclitaxel bioavailability for cancer treatment -- 5.1 Introduction -- 5.2 Alternative paclitaxel sources -- 5.2.1 Semisynthesis -- 5.2.2 Chemical synthesis -- 5.2.3 Nursery cultivated Taxus -- 5.2.4 Heterologous expression systems -- 5.2.5 Fungal endophytes -- 5.2.6 Corylus avellana. , 5.2.7 Plant cell culture -- 5.3 Strategies of paclitaxel biosynthesis improvement in plant cell culture -- 5.3.1 Selection of high-producing cell lines -- 5.3.2 Optimization of culture conditions -- 5.3.2.1 Two-stage culture -- 5.3.2.2 Carbohydrate source -- 5.3.2.3 Phytohormones -- 5.3.2.4 Ethylene inhibitors -- 5.3.3 Precursor feeding -- 5.3.4 Elicitation strategy -- 5.3.5 In situ product removal and two-phase culture -- 5.3.6 Immobilization -- 5.3.7 Metabolic engineering -- 5.3.8 Reactivation of paclitaxel biosynthesis pathway -- 5.3.9 Co-culture of plant cells with paclitaxel-producing fungal endophyte(s) -- 5.4 Mathematical modeling for paclitaxel biosynthesis optimization -- 5.5 Concluding remarks and future perspectives -- References -- 6 Botany of paclitaxel producing plants -- 6.1 History of taxol -- 6.2 Botany of Taxus -- 6.2.1 Classification of Taxus -- 6.2.2 Modern classification of Taxus species -- 6.3 Enumeration of taxol producing plant species -- 6.3.1 Austrotaxus spicata Campton (New Claedona Yew) -- 6.3.2 Pseudotaxus chienii (W.C. Cheng) W.C. Cheng (White Berry Yew) -- 6.3.3 Taxus baccata L. (European, English, or Common Yew) -- 6.3.4 Taxus brevifolia Nuttall -- 6.3.5 Taxus canadensis Marshall (Canada Yew) -- 6.3.6 Taxus chinensis (Pilg.) Rehd (Chinese Yew) -- 6.3.7 Taxus cuspidata Siebold et Zucc. -- 6.3.8 Taxus floridana Nuttall ex Chapman (Florida Yew) -- 6.3.9 Taxus globosa Schlectendahl (Mexican Yew) -- 6.3.10 Taxus meirei (Lemee & -- Lev.) S.Y. Hu ex T.S. Liu (Meires Yew) -- 6.3.11 Taxus sumatrana (Miquel) de Laubenfels (Tampinur batu) -- 6.3.12 Taxus wallichiana Zucc. (Himalayan Yew) -- 6.4 Taxol from angiosperms -- 6.4.1 Corylus avellana L. (common hazel or European hazel) -- 6.5 Conclusions and future direction -- References. , 7 Propagation of paclitaxel biosynthesizing plants -- 7.1 Introduction -- 7.2 Propagation -- 7.2.1 Vegetative propagation of Taxus spp. -- 7.3 Micropropagation -- 7.3.1 Embryo and seed culture to overcome seed dormancy -- 7.3.2 Somatic embryogenesis -- 7.3.3 Explant sources for micropropagation -- 7.3.4 Callus proliferation and organogenesis -- 7.3.5 Shoot topophysis -- 7.3.6 Rooting and acclimatization -- 7.4 Conclusions -- References -- 8 Endophytes for the production of anticancer drug, paclitaxel -- 8.1 Introduction -- 8.2 Paclitaxel sources in nature -- 8.3 Available approaches for paclitaxel production -- 8.4 Endophytes producing paclitaxel from different host plant species -- 8.5 Anticancer properties of endophytes-derived paclitaxel -- 8.6 Conclusions -- References -- 9 Metabolic engineering strategies to enhance the production of anticancer drug, paclitaxel -- 9.1 Introduction -- 9.2 Historical perspective of paclitaxel -- 9.3 Metabolic engineering strategies for paclitaxel production -- 9.3.1 Modulating the metabolic engineering strategy -- 9.3.1.1 Increasing the precursor access -- 9.3.1.2 Modulating (enhancing or decreasing) the effectors -- 9.3.1.3 Regulation of transcriptional factors -- 9.3.1.4 Dual production of Phyto-metabolites -- 9.3.2 Metabolic engineering in heterologous systems -- 9.3.3 Plant cell cultures and elicitation approaches to enhance paclitaxel production -- 9.4 Conclusions -- References -- 10 Paclitaxel and chemoresistance -- 10.1 Introduction -- 10.2 Mechanisms of chemoresistance -- 10.2.1 Alteration of microtubule dynamic -- 10.2.2 ABC transporters mediated MDR -- 10.2.3 Genetic factor-related paclitaxel resistance -- 10.2.4 Other potential mechanisms of resistance -- 10.2.4.1 PI3K/AKT activation -- 10.2.4.2 MAPK -- 10.2.4.3 Antioxidative systems -- 10.2.4.4 IRF9. , 10.2.4.5 Other key factors -- 10.3 Clinical markers of paclitaxel resistance -- 10.4 Strategies to overcome paclitaxel resistance -- 10.4.1 Overcoming paclitaxel resistance with novel tubulin inhibitors -- 10.4.2 Inhibiting the function of ABCB1 transporter -- 10.4.3 Inhibiting signal transduction pathways -- 10.5 Summary -- References -- 11 Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy -- 11.1 Introduction -- 11.1.1 Taxol/paclitaxel is a key agent in the management of solid tumors -- 11.2 Microtubule stabilization and anti-mitotic mechanisms -- 11.3 Mitotic catastrophe -- 11.4 Non-mitotic mechanisms -- 11.5 Importance of micronucleation -- 11.6 Innate immunity leading to the bystander effect -- 11.7 Cellular retention of paclitaxel -- 11.8 Combination therapy -- 11.8.1 Drug combination with paclitaxel: Carboplatin, FTI, CDK4/6, and PD1/PDL-1 -- 11.9 Prospective: New formulation of paclitaxel and additional microtubule stabilizing drugs -- 11.10 Conclusions -- References -- 12 An update on paclitaxel treatment in breast cancer -- 12.1 Introduction -- 12.2 Types of breast cancer -- 12.3 Molecular mechanism of paclitaxel in breast cancer -- 12.4 Paclitaxel treatment in different types of breast cancer -- 12.4.1 Metastatic breast cancer (MBC) -- 12.4.2 Inflammatory breast cancer (IBC) -- 12.4.3 Locally advanced breast cancer (LABC) -- 12.4.4 Molecular subtypes of breast cancer -- 12.5 Adverse events and resistance due to paclitaxel treatment -- 12.5.1 Side-effects -- 12.5.2 Paclitaxel resistance -- 12.6 Efficiency of other anti-cancer drugs over paclitaxel -- 12.7 Conclusions -- Acknowledgment -- References -- 13 Paclitaxel conjugated magnetic carbon nanotubes induce apoptosis in breast cancer cells and breast cancer stem cells i ... -- 13.1 Introduction. , 13.2 Experimental details.

Language: English

UID:

Format: 1 online resource (283 pages) : , illustrations

ISBN: 0-12-813680-4

Content: Advances in Cell and Molecular Diagnostics brings the scientific advances in the translation and validation of cellular and molecular discoveries in medicine into the clinical diagnostic setting. It enumerates the description and application of technological advances in the field of cellular and molecular diagnostic medicine, providing an overview of specialized fields, such as biomarker, genetic marker, screening, DNA-profiling, NGS, cytogenetics, transcriptome, cancer biomarkers, prostate specific antigen, and biomarker toxicologies. In addition, it presents novel discoveries and clinical pathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, and the description or polymorphisms linked to disease states. This book is a valuable resource for oncologists, practitioners and several members of the biomedical field who are interested in understanding how to apply cutting-edge technologies into diagnostics and healthcare.

Note: Chapter 1. Cellular and Molecular Diagnostics: An Introduction -- Chapter 2. RNA-Based Applications in Diagnostic and Therapeutics for Cancer -- Chapter 3. Advancements in Genetic Applications for Cellular and Molecular Diagnostics -- Chapter 4. Biomedical Imaging Role in Cellular and Molecular Diagnostics -- Chapter 5. Breast Cancer-Targeted Therapy Using Nanocarriers -- Chapter 6. Human Papillomavirus- and Epstein- Barr Virus-Caused Tumor Diagnosis and Therapy -- Chapter 7. Pathogen Identification Using Novel Sequencing Methods -- Chapter 8. Future of Cellular and Molecular Diagnostics: Bench to Bedside.

Additional Edition: ISBN 0-12-813679-0

Language: English